Hi Southoz, clyde's a good source of knowledge on this stock,...

Hi Southoz, clyde's a good source of knowledge on this stock, but here's my 2 bobs worth.

The trial is indeed of LondonPharma's 'patented sublingual spray delivery system' and the active ingredient in this case is an artemisin based anti-malarial product - the combined package is called ArTiMist.

(By way of background Protopharma were the original developers of the delivery system (specifically Dr Kelvin Ross) - they floundered Q4 last year, and LondonPharma came to the rescue and PP are now a subsidiary of LP.)

EMS hold the maunfacturing and distributions rights to ArTiMist - this is the product that EMS (probably) will offer up for trade sale. The EMS distribution rights for ArTiMist are not in question.

However, EMS previously contracted a German manufacturer (now in liquidation) called Berlin Pharma to manufacture ArTiMist. Given that this company is in liquidation we are all awaiting clarification by EMS on what this means for us.

Of some help is that EMS can outsource 10 million doses of ArTiMist to another manufacturer under the BP contract. EMS has confirmed recently that BP liquidators can on sell the manufacturing rights. Originally EMS was a major shareholder in BP but am unsure if onselling the manufacturing rights will be of any financial benefit to EMS.

There are still some risks in this stock but funding seems to be OK with recent notification of convertible notes, Phase 3 trials are almost fully enrolled and the CEO seems a resonable chap.

Any advise from EMS about resolution of some of the risks should be share price accretive and notification of the trade sale is what everyone is waiting for.

bluebush